BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
TYK2 Inhibitor Grows Bristol’s Immunology Franchise
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
You may also be interested in...
BMS reiterated its 2024 focus on execution across its portfolio and R&D pipeline as it works through upcoming losses of exclusivity, and its fourth quarter revenues reflected year-end efforts to drive sales.
Ventyx’s TYK2 inhibitor met primary and secondary endpoints in a Phase II psoriasis trial, but the biotech determined the data are not competitive in a class led by Bristol’s Sotyktu.
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.